Market Overview:
SARS (Severe Acute Respiratory Syndrome) is a viral respiratory disease caused by a SARS-associated coronavirus. SARS was first identified during the outbreak in China in late February 2003 and has spread to 4 other countries. In affected countries, the World Health Organization worked with health authorities to provide clinical, epidemiological, and logistical support, as well as to bring the outbreak under control. While, SARS‐CoV‐2, the novel coronavirus, is the virus that causes COVID-19 (coronavirus disease), the respiratory illness responsible for the ongoing pandemic. Both SARS and COVID-19 are caused by SARS-associated coronaviruses. The infections occur in both animals and humans, and may lead to death. Therefore, there is an increasing demand for severe acute respiratory syndrome (SARS) treatment, worldwide.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4494
Competitive Landscape:
Major players active in the global severe acute respiratory syndrome (SARS) treatment market are AstraZeneca Plc., Eli Lily & Company, Boehringer Ingelheim, Johnson & Johnson, Ipca laboratories, Takeda Ltd., AbbVie, Roche Holding AG, Pfizer Inc., Novartis, GlaxoSmithKline plc., Cadila healthcare Ltd., Cipla Ltd., Hetero labs Ltd., and Gilead Sciences Inc.
Key Market Drivers:
Increasing cases of COVID-19 around the world is expected to boost the growth of the severe acute respiratory syndrome (SARS) treatment market during the forecast period. For instance, according to the World Health Organization (WHO), globally, as of 5:40pm CET, 2 November 2021, there have been 246,951,274 confirmed cases of COVID-19, including 5,004,855 deaths.
Moreover, introduction of novel drugs and vaccines and/or increasing drug approvals for the treatment of both SARS and COVID-19 is expected to augment the growth of the severe acute respiratory syndrome (SARS) treatment market. For instance, in October 2020, the U.S. Food and Drug Administration (FDA) approved the antiviral drug Veklury (Remdesivir) for the use in adult and pediatric patients for the treatment of COVID-19. Veklury is the first treatment for COVID-19 to receive FDA approval.
COVID-19 Impact Analysis:
The outbreak of COVID-19 was initially noticed in a seafood market in Wuhan, China in mid- December 2019, has now spread to 215 countries/territories/areas worldwide. Most individuals infected with COVID-19 experience mild to moderate respiratory illness and recover without treatment, whereas some become seriously ill and require medical attention. The rapid pace of the coronavirus disease caused many research efforts to be initiated quickly. China has more than 80 running or pending clinical trials on potential treatments for COVID-19. Moreover, the governments around the world are focusing on vaccination to prevent the spread of the virus. According to WHO, as of 1 November 2021, a total of 6,893,866,617 vaccine doses have been administered worldwide. This n turn is expected to propel the market growth.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/4494
Key Takeaways:
- The severe acute respiratory syndrome (SARS) treatment market is expected to exhibit a CAGR of XX % during the forecast period owing to the increasing number of clinical trials for the development of safe and effective SARS treatments. For instance, in March 2020, WHO launched a multiarm, multi-country clinical trial for potential coronavirus therapies, part of an aggressive effort to jumpstart the global search for drugs to treat COVID-19.
- Among regions, North America and Asia Pacific are expected to witness robust growth in the severe acute respiratory syndrome (SARS) treatment market owing to rising number of COVID-19 cases, increasing demand for safe and effective vaccines, government funding for vaccine development, fast regulatory approvals, and the increasing awareness regarding the potential value of vaccination in these regions.
For instance, in September 2021, Pfizer Inc. and Merck & Co Inc. announced new trials of their experimental oral antiviral drugs to treat COVID-19; as the race to develop an easy-to-administer treatment for the potentially fatal illness heats up.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/4494
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Severe Acute Respiratory Syndrome (SARS) Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Severe Acute Respiratory Syndrome (SARS) Treatment Industry Impact
Chapter 2 Global Severe Acute Respiratory Syndrome (SARS) Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Severe Acute Respiratory Syndrome (SARS) Treatment (Volume and Value) by Type
2.3 Global Severe Acute Respiratory Syndrome (SARS) Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Severe Acute Respiratory Syndrome (SARS) Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 6 East Asia Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 7 Europe Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 8 South Asia Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 9 Southeast Asia Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 10 Middle East Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 11 Africa Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 12 Oceania Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 13 South America Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Severe Acute Respiratory Syndrome (SARS) Treatment Business
Chapter 15 Global Severe Acute Respiratory Syndrome (SARS) Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
Continued….
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837